Skip to navigation Skip to content

Chronic kidney disease-associated pruritus (CKD-aP) Program in Pharmaceutical Benefits Scheme (PBS) 012-24041207

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised difelikefalin (pronounced “dye-fel-i-KEF-a-lin”) for patients with chronic kidney disease-associated pruritus (CKD-aP).

CKD-aP and listing dates

CKD-aP is very itchy skin that is most common in patients with advanced chronic kidney disease.

Listing dates: difelikefalin - 1 May 2024.

See Written Authority Required Drugs, for more details.

Treatment specifics

The patient must be at least 18 years of age.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs, and choose the option relevant to the condition treated.

The Resources page contains:

  • contact details
  • restriction and item codes
  • FAQs from Service Officers
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings